AGC Biologics Completes Milestone at New Manufacturing Building in Copenhagen
AGC Biologics completes milestone at new state-of-the-art manufacturing building in Copenhagen, doubling mammalian manufacturing capacity and starting production on a phase II/III clinical project.
This news matters because it demonstrates AGC Biologics' commitment to expanding its manufacturing capabilities, providing more treatment options, and serving as a top location for developer partners seeking CDMO services in Europe. The successful completion of the milestone also reflects the company's dedication to continuous innovation and solving clients' most complex challenges.
